The prognostic role of preoperative circulating neutrophil-lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis

World J Urol. 2019 Sep;37(9):1817-1825. doi: 10.1007/s00345-018-2593-z. Epub 2018 Dec 3.

Abstract

Background: Systemic inflammatory response (SIR) plays important roles in initiation, promotion and progression of tumor. However, the prognostic role of preoperative circulating neutrophil-lymphocyte ratio (NLR) (known as a marker of SIR) in human primary bladder cancer (BC) undergoing radical cystectomy (RC) remains controversial. Hence, we performed this meta-analysis to better understand the role of preoperative circulating NLR in prognosis prediction for primary BC patients undergoing RC.

Methods: We searched PubMed, Embase and EBSCO to identify the studies and computed extracted data with STATA 12.0.

Results: A total of 11,945 patients with BC from 18 published studies were incorporated into this meta-analysis. We found that elevated NLR was significantly associated with decreased 3-year and 5-year overall survival (OS), 1-year, 3-year and 5-year recurrence-free survival (RFS), but not with 1-year or 10-year OS, or 10-year RFS in primary BC patients who underwent RC. The results also showed that neoadjuvant chemotherapy (NAC) had a significant impact on the negative prognostic effect of NLR. In addition, high NLR significantly correlated with unfavorable clinicopathological features of BC.

Conclusion: Elevated preoperative circulating NLR leads to an unfavorable outcome in primary BC undergoing RC, especially in patients without NAC, implicating that it might be a valuable prognostic index for these patients.

Keywords: Meta-analysis; Neoadjuvant chemotherapy; Preoperative circulating neutrophil–lymphocyte ratio; Primary bladder cancer; Radical cystectomy; Unfavorable outcome.

Publication types

  • Meta-Analysis

MeSH terms

  • Cystectomy* / methods
  • Humans
  • Leukocyte Count
  • Lymphocytes*
  • Neutrophils*
  • Preoperative Period
  • Prognosis
  • Urinary Bladder Neoplasms / blood*
  • Urinary Bladder Neoplasms / surgery*